

The Ataxia Telangiectasia Society Trustees' Report and Accounts 2022



Welcome to the Ataxia Telangiectasia (AT) Society.

We are a small, national charity supporting children, adults and their families whose lives have been shattered by a diagnosis of AT, a rare, degenerative, life-limiting condition for which there is no cure or treatment. Our purpose is to improve the quality of life and quality of care for people living with AT while actively promoting research to improve treatments and ultimately bring about a cure. We are the only charity in the UK providing specialist practical and therapeutic support for people affected by AT.

“Our greatest strength has been our network of fantastic supporters; fundraisers, donors, medics, scientists, and families affected by AT.”

Mike Detsiny
Chair of Trustees

- 1 Chair of Trustees' statement
- 2 Trustees' report
- 9 Independent auditor's report
- 12 Statement of financial activities
- 13 Statement of financial position
- 14 Statement of cash flows
- 15 Notes to financial statements
- 21 Trustees, patrons and advisors

Chair of Trustees' statement

For most people, 2022 was another extremely challenging year. On top of COVID, which continued to impact the lives of everyone in the UK in all sorts of ways, most households also experienced financial pressure from unprecedented price increases and rising inflation. Sadly, people affected by ataxia telangiectasia, were disproportionately adversely affected by this turbulence.



The higher cost of specialist equipment, use of everyday essentials and energy, all made it harder for AT households to meet the extra cost of disability. Added to these tensions, the increasing pressures on NHS mental health teams, have made it considerably harder for people affected by AT to gain access to services even though living with a rare disease substantially impacts mental health.*

At the same time, we also faced another year of risks to income as the economic crisis impacted on donors' giving capacity, and our own costs increased. Whilst we had some terrific fundraising success stories – grants from Trusts and Foundations increased and support from companies increased ninefold from the previous year meaning overall we increased income by 16.5% – at the same time individual donations fell by 20% and event income remains woefully below pre-pandemic levels.

In the expectation that these economic pressures and the enormous social welfare restrictions will continue, we have invested in fundraising to help to continue to lift income, we have managed our operational costs and reduced our deficit, and we have taken steps to ensure our reserves are invested at a level to maximise returns, so that we can face the future with some optimism and achieve our ambitious plans for the years ahead.

So, for now, let's take a moment to celebrate our successes. We are proud of what we've achieved in 2022 with our partners and supporters, and the impact we've had. We have responded to over 800 vital phone calls from individuals with AT and family members in crisis, increased our professional counselling support by 8%, and helped young people and families to feel less alone because of the advice, support, and social connections we've provided.

We have joined other charities in the fight for disability equality, and provided 30 emergency grants to help families pay for fuel bills, specialist mobility equipment, urgent housing adaptations and respite activities. We have answered 216 urgent calls from health and social care professionals, and held 197 zoom meetings, so that professionals can effectively and sensitively recognise and address patients' and carers' health, education, housing, and financial needs. And to catch up on the covid-backlog, additional specialist AT medical clinics were organized through the year with our NHS partners, increasing our associated costs by 40%.

In 2022, we also committed to funding new research studies to advance our understanding of the condition, and we supported people with AT to participate in clinical trials where affordability prevented them from doing so. Together with our international scientific, medical, and financial partners we are pleased that we are moving closer towards finding treatments and ultimately a cure for AT.

Our greatest strength has been our network of fantastic supporters; fundraisers, donors, medics, scientists, and families affected by AT. Thank you for being with us. And thank you to all our volunteers and staff who have worked with skill, determination, and heart to achieve the things we've been able to. You have all played a vital part in helping to provide care and support for today and hope for tomorrow, and we are forever grateful.

Mike Detsiny
Chair of Trustees

*90% of individuals with a rare disease and their carers, feel anxious, stressed, and depressed. 36% of patients and 19% of carers had had suicidal thoughts. (BMC Health Services Research, vol 22, 2022, Spencer Tansley et al.)

The AT Society's Board of Trustees have pleasure in presenting their report, together with the Society's audited financial statements for the year ended 31 December 2022.

This report has been prepared in compliance with the duty in Section 17 (5) of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

The trustees, who are directors of the company for the purposes of the Companies Act, have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (Charities SORP FRS 102) (effective 1 January 2019).

Objectives and activities

The purpose of the Society, as set out in the company's Memorandum of Association, is "the relief of sickness and distress among persons suffering from ataxia telangiectasia".

Vision

A world where no one need suffer from the devastating effects of AT.

Mission

To improve the quality of life and quality of care for people living with AT while actively promoting research to improve treatments and ultimately bring about a cure.

We do this by:

- Providing specialist information, support, care and advocacy to meet the challenges of living with AT
- Speaking out to ensure that the voices of people affected by AT are heard
- Raising awareness of AT
- Working to achieve better, more informed, and more coordinated health and social care services across all sectors
- Promoting and commissioning high quality AT research.

During 2022, we ensured the Society's objectives were always in line with our mission.

In undertaking our work, we are dedicated to ensuring people affected by AT can live the best lives possible, and are supportive, empowering, respectful, and professional in all we do. Where we come up against barriers, we seek agile and innovative solutions to ensure we can be there for those who need us.

And we are collaborative, working in partnership with AT experts in the UK and across the world to maximise influence, awareness, and knowledge.

Ensuring the Society's work achieves its aims and delivers public benefit

The Memorandum of Association sets out the charitable purposes for public benefit. The trustees review the Society's aims, objectives and activities each year during the planning cycle. This review examines the activities of the previous year and measures the outcomes of those activities against the objectives of that year's plan by reference to the benefits delivered to people affected by AT. It also serves to ensure that the Society's aims and objectives remain focused on its stated purpose and enables the trustees to consider how the Society's activities further its charitable purposes for the public benefit, in accordance with the Charity Commission's guidance.

The Society has a formal budgeted business plan for the year, which is reviewed regularly, in accordance with the key objectives above.

The Society's activities and achievements in pursuit of these objectives in 2022 are detailed below. We have set out specific examples of activities in our Impact Report, which complements this report (www.atsociety.org.uk/about-us).

Achievements and performance

This was an exceptional year as the continuation of COVID and uncertainties around future restrictions, the increased mental health issues, the severe lack of government funding of social care, and the beginnings of double-digit inflation resulted in tough times for many, and none more so than those affected by ataxia telangiectasia.

Throughout the year people affected by AT continued to face unfair extra costs. The higher cost of specialist equipment, higher usage of everyday essentials and energy, the continuous fight to receive the correct disability benefit, all made it harder for AT households to meet the extra cost of disability. Refugee families affected by AT especially faced a disproportionate struggle to get the right support and respect.

Against that backdrop, it can be easy to lose hope, but at the AT Society optimism continued to shine.

In furtherance of our aims, we supported 225 individuals with AT and their family members, representing a 5% increase on last years numbers.

How we changed lives in 2022



We increased the emergency financial support we were able to provide to help with food and energy bills, respite care and housing support, and we increased our bespoke mental health provision to ensure that as NHS waiting lists for mental health care kept growing, we were able to be there for people with AT.

We are proud that we ensured that families affected by AT felt less alone, because of the advice and support we were able to give; that young people were able to stay connected and felt more fulfilled because of the social activities we ran; that medical queries were answered as the number of AT specialist clinics doubled to deal with the backlog

from the pandemic; and that parents with a newly diagnosed child were given hope because of the investments in medical research we have been able to make in the year.

The AT Society clinic continues to be a crucial element of our work with AT families, not only in the delivery of essential medical care by AT experts, but also in helping to join up the national service with local health and social care teams.

Our involvement in the two unique, dedicated AT clinics at Nottingham University Hospital and the Royal Papworth Hospital, is essential to their operation. From the organisation of families' transport and individual appointments with clinicians, to the funding

of accommodation and food and the attendance of our team being on-hand to offer emotional support, advice and professional counselling, this bespoke service is extremely valuable. Feedback demonstrated that 100% of families attending the clinics would be keen to visit again in future and 83% reported valuing meetings with our Family Support team prior to their medical appointments.

The COVID backlog put increased pressure on this service and as a result we ran 3 extra clinics in the year and will do so again in 2023 to ensure that everyone in the UK with AT can reap the benefits of AT clinics.

"We're so grateful to receive emotional, physical and mental support from professionals who understand about AT."

This year we were pleased to be able to create a series of films showing our specialist clinics. These are designed for children and their families new to clinic, to reduce any anxieties prior to attending and increase their understanding of what to expect.

Thanks to our wonderful supporters and to the excellent AT research community, we have also been able to continue investing in medical research. In 2022, we committed to supporting 6 new important research studies and to continuing to fund 4 ongoing projects. All of these studies are essential in advancing our understanding of the condition, driving us towards better treatments and moving us closer to a cure for AT.

Some examples of the work we are funding are detailed in our Impact Report, and can be found here: www.atsociety.org.uk/about-us/our-publications-and-films/our-annual-report-and-accounts/

It was also an exciting year in the field of clinical trials, as some encouraging results were reported, and new trials discussed. EryDel's international trial to assess a treatment to slow the progression of ataxia in AT, for instance, reported positive outcomes; IntraBio announced optimistic results in alleviating ataxia symptoms; and Adrestia Therapeutics continued their journey towards their development of new drugs to correct the underlying disease biology of AT.

In the year we diverted some of our funding to keep UK families involved and to ensure financial hardship was not a barrier to their children's participation.

We have not achieved this alone. As part of our everyday work we've worked in partnership with experts across the world and across different

sectors, to make this happen. Our experts include people with lived experience of AT, who have been, and always will be, central to all we have achieved. Our Board of Trustees with 55% representation of lived experience, our user consultations, our WhatsApp groups with young people with AT, and our Scientific Advisory Board with parent representatives, all ensure that the delivery of our services is shaped by those who know best.

Plans for future periods

The Society's plans for 2023 and the following years are built around our priority areas of:

- › Supporting people affected by AT to live well with AT
- › Improving provision of information and active communication around AT
- › Increasing the impact of our research programme and strengthening cooperation across the AT research community
- › Strengthening and increasing the diversity of our fundraising.

We will do this by continuing to focus on developing our mental health work to help people to cope with the challenges that AT brings and will be led by the insights of people affected by AT. We will provide expert and friendly advice and support to all service users, their families, and professionals. And we will fight for the overlooked needs of disabled people and stand up to the injustices that make life harder for people with AT.

Key priorities will be to: work with our NHS partners to run more of our specialist AT medical clinics to continue catching up on the COVID backlog; deliver in person events with beneficiaries to improve social opportunities and mental wellbeing; progress our work to ensure all our services are fully accessible; continue our equity, diversity and inclusion ambitions and develop an action plan to guide our next steps in this area; recruit a part-time fundraiser and organise new fundraising events.

We will also continue our efforts to reduce our carbon footprint by moving closer to becoming a paperless office, reducing travel by meeting online where possible; recycling waste and equipment; and buying environmentally friendly products.

Financial review

During the year we were pleased to have increased our income, controlled costs and significantly reduced our deficit.

The AT Society received income of £429,145 (2021: £368,340) and spent £481,406 (2021: £500,634).

The Society therefore had an overall deficit for the year of £52,261 (2021: £132,294). With funds brought forward from previous years, the Society will carry forward £583,989 in reserves (2021: £636,250).

Unrestricted general funds carried forward have increased to £364,843 (2021: £324,532). The Society also carries forward restricted funds of £219,146 (2021: £311,718), which the trustees consider to be at an appropriate level.

Of the Society's total income some 49.6% was received in donations from individuals, companies and trusts; 49.5% in grants from NHS England, the European Commission, the Medical Research Council and Trusts. The remaining income came from trading and investment income.

Investment policy

The trustees recognise their duty to maximise the financial returns generated from the way in which the charity's assets are invested and do so responsibly and ethically in a way that is consistent with the aims and values of the AT Society. In 2022 the trustees evaluated the investment returns and agreed to move funds from a deposit account with the Charities Aid Foundation, to a more flexible deposit platform with Flagstone, still managed by CAF, and which involves investing in UK banks with higher interest-bearing returns and no risk of capital loss. The senior management and trustees monitor the investments regularly.

Reserves policy

The AT Society maintains free unrestricted reserves:

- ▶ to provide a level of working capital that protects the continuity of our core work
- ▶ to provide a level of funding for unexpected opportunities
- ▶ to provide cover for risks such as unforeseen expenditure or unanticipated loss of income.

The Board of Trustees regularly review the above criteria with reference to the AT Society's strategy and Annual Plan and determine the target level of free reserves to meet these.

Given the turbulent economic climate and the risks to income and cost increases, in 2022 the Board considered it prudent for a charity of this size, heavily reliant upon voluntary income, to maintain a minimum level of 9 months of operational costs. In 2023 this will amount to unrestrictive reserves of approximately £350,000.

The Board of Trustees will at times designate funds from free reserves for significant project costs or replacement of major assets.

The charity also holds restricted reserves which represent the excess of restricted income over restricted expenditure. Restricted reserves are closely monitored to ensure they are used in accordance with the terms specified when the funds were received.

Our operational budget currently includes a planned deficit in recognition of the investment in research and support services that the Society committed to during the year.

Fundraising

Whilst the AT Society engages in public fundraising, it does not use external professional fundraisers or commercial participators for this. However, professional fundraisers are used for fundraising from Trusts and Foundations. The charity observes and complies with the relevant fundraising regulations and codes and is a member of the Fundraising Regulator.

The AT Society is committed to safeguarding any personal fundraising data that we process, ensuring that it is stored and shared safely and securely. We are compliant with GDPR and review all data privacy and protection policies regularly to ensure that they remain strong and effective.

Structure

The Society is a charitable company limited by guarantee, incorporated in England and Wales, and registered with the Charity Commission in England. The company was established under a Memorandum of Association which defined its objects and powers; it is governed by its Articles of Association. In the event of the company being wound up members may be required to contribute an amount not exceeding £1 each.

Directors of the company are also trustees for the purposes of charity law. The directors are normally referred to as 'trustees' and in normal years meet formally as a Board 4 times each year. Through the pandemic trustees met monthly in order to keep abreast of challenges the coronavirus brought. The Board of Trustees is the governing body of the Society. It agrees the overall strategy for the organisation and the policies and procedures for the implementation of this strategy. It also oversees the effective and equitable use of the Society's resources and ensures that it meets all its legal, regulatory and ethical obligations.

Our research work is overseen by our Scientific Advisory Board, who report to the main Board. The membership of the SAB is listed on the inside back cover of this report. Our research applications undergo a rigorous peer reviewed process and only those deemed to be of the highest quality are passed for funding. We are regulated by the Association of Medical Research Charities.

The Society's staff team is based at the offices in Harpenden. The Director of Fundraising & Operations shares leadership of the charity with the Head of Services and Head of Research. Remuneration of the Society's staff team of 8 is reviewed annually against performance and affordability. The team organises and provides the vast majority of the services delivered by the Society and manages and supports the Society's volunteers.

Governance and management

The Board of Trustees may consist of between 3 and 20 members. Under the terms of the Memorandum and Articles of Association, directors may either be appointed by the Board to fill a casual vacancy or are to be elected by the Society's members at the annual general meeting to serve a 3 year term of office. All appointed directors must submit themselves to election at the annual general meeting immediately following their appointment.

All directors of the company give their time voluntarily and receive no benefit from the charity by virtue of the office they hold. Any expenses reclaimed from the charity are set out in note 10 to the accounts. Where a director is a potential beneficiary of the charity, the holding of his office will not be a bar to his or her being an actual beneficiary. In such circumstances, the director declares his interest and takes no part in the discussion or decision concerning his or her application for benefit.

All trustees active in 2022 are listed on the inside back cover of this report. In accordance with our aim to be a user-led organisation, over half of our Board have experience of living with AT.

Trustee induction and training

Vetting and checks of trustees is carried out in line with Charity Commission guidance. All new trustees receive an information pack outlining their legal obligations under charity and company law, a copy of the previous year's annual report and accounts, a copy of the annual plan, a copy of the company's Memorandum & Articles of Association and a representative selection of the Society's current literature. Inductions take place with all staff.

The Board has a positive approach to its own training and development, regularly reviewing skills and needs and organising appropriate training, whether for the group or for individuals. All trustees complete safeguarding training appropriate for their role and all are encouraged to keep abreast of developments both in charity governance and in current issues concerning AT.

Staff

The Society values its staff and aims to be an exemplary employer of a skilled and committed workforce. It does not discriminate in any way in the recruitment, training or retention of employees.

The Society actively encourages its staff to enhance and extend their skills, particularly with regard to its charitable objectives, and learning and personal development are central to the appraisal process.

During the year we enjoyed the support of office, administrative, event volunteers and volunteers from companies who gave communications and design support, legal and administrative help, for which we are immensely grateful.

Collaborations

The Society is a national organisation operating throughout the UK and collaboration is at the heart of what we do. It is essential that we work closely with all organisations and individuals connected to AT and we are proud that joining with experts across the world and across different sectors is part of our everyday work.

Our involvement in establishing the Global A-T Alliance in 2020, is a good example (www.cureat.org/). The Alliance has a strong collective belief that together we are stronger and through 2022 delivered a range of shared activities. The connections give small international AT organisations access to vital skills, knowledge, and experience, while working towards the same overall vision: to improve lives for people affected by AT and to find a cure.

To strengthen our ability to campaign on behalf of and meet the needs of people living with AT, we are affiliated to:

- Genetic Alliance UK
- Rare Disease UK
- The Association of Medical Research Charities ("AMRC")
- Euro-Ataxia

We are members of the NCVO and we work closely with Ataxia UK. For instance, the Head of Ataxia

Research assists the AT Society in the implementation of the AT Society's research strategy.

Our long-established AT Clinical Research Network brings together researchers, clinicians and patient organisations from around the world and is a very active and useful body.

Our AT clinics (the world's first) provide an integrated service for people living with AT, funded and supported by NHS England. We work closely with the professional arms of the service: the specialist AT centres at Nottingham University Hospital (paediatric), the Royal Papworth Hospital (adult) and the diagnostic services. The centres of excellence have developed a unique expertise in this field and provide multi-disciplinary AT clinics.

Our specialist clinics and our strong links with those medics in the world with expertise in AT mean that we can successfully act as an important point of contact for local professionals seeking expert opinion. Most have little in-depth knowledge of AT and so our role here is imperative. Equally we help ensure recommendations from clinic professionals are understood and implemented by patients' local health teams to speed up access to health.

Risk management

The trustees have a risk management process which includes an annual review of the risks to which the charity may be exposed, and the establishment and implementation of systems and procedures designed to mitigate the impact on the charity of the risks identified. In the current challenging times, the risk register is reviewed frequently. Key risk areas identified for 2023 include:

- Insufficient funds to allow the charity to meet its objectives
- Information security and data protection
- Safeguarding children, young people and vulnerable adults
- Loss of key staff.

Safeguarding

Protecting the welfare of children, young people and vulnerable adults who receive the services we provide is central to our culture and is a governance priority. Everyone who works or volunteers for the AT Society has a responsibility to safeguard and promote service users' welfare, alongside a duty to recognise, respond and share concerns or worries about possible abuse and harm in a timely fashion. This is reflected in our safeguarding policies and procedures, which include safe recruitment

measures and clear training requirements, which are regularly reviewed by our safeguarding leads.

Grant-making policies

The Society makes two types of grant to meet its objectives:

- Individual support grants
- Research grants

Research grants

The Society is a member of the Association of Medical Research Charities (AMRC) and works to AMRC standards in its research grant programme. Our Scientific Advisory Board ensure that research grants undergo a robust peer-reviewed process and confirm that:

- The project has scientific merit and meets the aims of the Society's research strategy
- The proposed study does not duplicate other current or recent research
- The Society is spending its research funds in the most effective way

The AT Society's research strategy and procedures are reviewed by the SAB and reported to the trustee board, with priorities agreed to ensure the greatest possible impact for its research programme.

For the next few years, the AT Society is primarily focusing its research efforts on understanding and treating the neurological problems caused by AT and the loss of the ATM protein. This is the feature of AT which has the greatest impact on everyday life for people with AT. It not only affects movement and manual dexterity, but also speech, eating and nutrition, posture and potential scoliosis and it also contributes significantly to the development of lung disease.

In line with our research strategy, during 2022 we supported various research projects. Some we are co-funding and some we fund alone:

- Natural History of AT (N-HAT), and a statistical consultancy, University of Nottingham
- The use of ultrasound in the assessment of people with AT's ability to swallow versus use of video fluoroscopic, Royal Papworth Hospital
- Brain-penetrating ATM gene therapy, University of Nottingham
- Study of natural killer cells in AT pathogenesis and their therapeutical implications, Tor Vergata University of Rome

- › Digital drug prediction informed by genetic analysis of stem cell-derived mini brains from AT patients, QIMR Berghofer Medical Research Institute
- › Understanding and correcting glucose metabolism defects in AT, The FIRC Institute of Molecular Oncology
- › Trial REadiness in AT, University of Cambridge
- › Modulation of RELB/p52-dependent NF-kB activities to improve neurodegenerative symptoms of AT, University of Cambridge
- › Functional and metabolomic analysis of iPSC-derived Purkinje neurons from AT patients, FIRC Institute of Molecular Oncology, Milan.

Our full research programme can be viewed at:
www.atsociety.org.uk/research/

Individual support grants

The Society provides financial support grants to any individual affected by AT, to assist with the cost of items that they need as a result of the condition but cannot easily afford, and for which they cannot get help from other sources. An application form is used and there are formal criteria for the assessment and awarding of grants, approved by the AT Society Support Team. Applicants need the support of an appropriate professional and need to demonstrate what efforts have been made to obtain statutory or other funding.

Legal and administrative information

The Ataxia Telangiectasia Society is a charitable company limited by guarantee, incorporated in England and Wales, in 2004, under company number 5177145. It is registered with the Charity Commission in England under the same name, registration number 1105528. The Society uses the working name "AT Society". The registered address is listed on the inside back cover.

Statement of trustees' responsibilities

The trustees (who are also the directors of The Ataxia Telangiectasia Society for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the

charitable company for that period. In preparing those financial statements, the trustees are required to:

- › Select suitable accounting policies and then apply them consistently
- › Observe the methods and principles in the charity SORP
- › Make sound judgements and estimates that are reasonable and prudent
- › Prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Society will continue on that basis.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006.

The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In accordance with company law, as the directors of the company, we certify that:

- › So far as we are aware there is no relevant audit information of which the company's auditors are unaware
- › As the trustees of the company, we have taken all the steps that we ought to have taken in order to make ourselves aware of any relevant audit information and to establish that the charity's auditors are aware of that information.

Auditors

Hicks and Company, the auditors, were re-appointed as the charitable company's auditors during the year and have expressed their willingness to continue in that capacity. A resolution will be proposed at the annual general meeting that they be re-appointed as auditors to the charity for the ensuing year.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the Board of Trustees on 17 July 2023 and signed on its behalf by:

David MacDonald
Treasurer

Independent auditor's report to the members of The Ataxia Telangiectasia Society

Opinion

We have audited the financial statements of The Ataxia Telangiectasia Society (the 'charitable company') for the year ended 31 December 2022 on pages 12 to 20. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- ▶ Give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- ▶ Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- ▶ Have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- ▶ The information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- ▶ The Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- ▶ Adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- ▶ The financial statements are not in agreement with the accounting records and returns; or
- ▶ Certain disclosures of trustees' remuneration specified by law are not made; or

- › We have not received all the information and explanations we require for our audit; or
- › The trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities set out on page 8, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the entity and sector in which it operates, we identified the principal risks of non-compliance with laws and regulations relating to charitable companies and the application

of charitable funds. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud may occur, by making enquiries of the trustees and management as to where they considered there was susceptibility to fraud and considering the internal controls in place to mitigate fraud risks and non-compliance with laws and regulations.

In response to the risk of fraud through management bias (including the risk of override of controls) and the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- › Performing analytical procedures to identify unusual or unexpected transactions
- › Assessing whether judgements and assumptions made in determining accounting estimates were indicative of potential bias
- › Reviewed a sample of transactions from the client's records for proper authorisation
- › Performing completeness of income tests
- › Test checking the appropriateness of journal entries
- › Agreeing financial statement disclosures to the underlying supporting documentation
- › Checking for correspondence with the Charity Commission
- › Reading the minutes of Trustees' meetings
- › Checking for any actual and potential litigation and claims including inspecting legal costs.

There are inherent limitations in our audit procedures outlined above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any. Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Philip Dean

Senior Statutory Auditor

For and on behalf of Hicks and Company

Chartered Accountants and Statutory Auditor

Vaughan Chambers

Vaughan Road

Harpenden

Hertfordshire AL5 4EE

17 July 2023

Statement of financial activities

Year ended 31 December 2022

	Notes	Unrestricted funds £	Restricted funds £	Total funds 31.12.22 £	Total funds 31.12.21 £
Income and endowments from:					
Donations and legacies	2	206,327	219,084	425,411	367,087
Charitable activities					
Other trading activities	3	1,592	–	1,592	1,190
Investment income	4	2,142	–	2,142	63
Total		210,061	219,084	429,145	368,340
Expenditure on:					
Raising funds	5	117,439	–	117,439	92,811
Charitable activities	6				
Research		57,278	1,079	58,357	179,939
Clinic		34,592	56,906	91,498	65,210
Welfare		602	120,047	120,649	81,756
Information		31,097	7,715	38,812	30,132
Education		21,555	–	21,555	17,987
Governance		33,096	–	33,096	32,799
Total		295,659	185,747	481,406	500,634
Net (expenditure)/income		(85,598)	33,337	(52,261)	(132,294)
Reconciliation of funds					
Total funds brought forward		324,532	311,718	636,250	768,544
Transfers between funds		125,909	(125,909)	–	–
Total funds carried forward		364,843	219,146	583,989	636,250

The statement of financial activities includes all gains and losses in the year.
All incoming resources and resources expended derive from continuing activities.

The notes on pages 15 to 20 form part of these financial statements.

Statement of financial position

Year ended 31 December 2022

	Notes	Unrestricted funds £	Restricted funds £	Total funds 31.12.22 £	Total funds 31.12.21 £
Fixed assets					
Tangible assets	13	2,251	–	2,251	1,931
Current assets					
Debtors	14	16,641	77,497	94,138	157,258
Cash at bank		357,460	201,099	558,559	613,863
		374,101	278,596	652,697	771,121
Creditors:					
Amounts falling due within one year	15	(11,509)	(59,450)	(70,959)	(136,802)
Net current assets		362,592	219,146	581,738	634,319
Total assets less current liabilities		364,843	219,146	583,989	636,250
Net assets		364,843	219,146	583,989	636,250
Funds:	17				
Unrestricted funds				364,843	324,532
Restricted funds				219,146	311,718
Total funds				583,989	636,250

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies.

The notes on pages 15 to 20 form part of these financial statements.

The financial statements were approved by the Board of Trustees on 17 July 2023 and were signed on its behalf by:

David MacDonald
Treasurer

Statement of cash flows

Year ended 31 December 2022

	Notes	31.12.22 £	31.12.21 £
Cash flows from operating activities:			
Cash used in operations	a	(56,162)	(175,693)
Net cash used in operating activities		(56,162)	(175,693)
Cash flows from investing activities:			
Purchase of tangible fixed assets		(1,284)	(504)
Interest received		2,142	63
Net cash used in investing activities		858	(441)
Change in cash and cash equivalents in the reporting period		(55,304)	(176,134)
Cash and cash equivalents at the beginning of the reporting period		613,863	789,997
Cash and cash equivalents at the end of the reporting period		558,559	613,863

Notes to the statement of cash flows

Year ended 31 December 2022

a. Reconciliation of net (expenditure)/income to net cash flow from operating activities

	31.12.22 £	31.12.21 £
Net expenditure for the reporting period as per the statement of financial activities	(52,261)	(132,294)
Adjustments for:		
Depreciation charges	964	794
Interest received	(2,142)	(63)
(Increase)/decrease in debtors	63,120	(115,487)
Increase/(decrease) in creditors	(65,843)	71,357
Net cash used in operating activities	(56,162)	(175,693)

Notes to financial statements

Year ended 31 December 2022

1. Accounting policies

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All incoming resources are included in the Statement of Financial Activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

- ▶ Voluntary income is received by way of grants, donations and gifts. Donations and gifts are included in the Statement of Financial Activities when received. Grants are included when receivable. Grants, where entitlement is conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to them
- ▶ Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included in these accounts
- ▶ Investment income is included when receivable. Bank interest is included when received
- ▶ Tax refunds (e.g. gift aid) are accounted for when receivable
- ▶ Trading income is accounted for on a receivable basis.

Expenditure

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes VAT, which cannot be recovered, and is reported as part of the expenditure to which it relates:

- ▶ Costs of generating funds comprise the costs associated with attracting voluntary income
- ▶ Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such

activities and those costs of an indirect nature necessary to support them

- ▶ Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees. All costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resources. Costs relating to a particular activity are allocated directly, other costs are apportioned on an appropriate basis e.g. estimated usage.

Leases

Rentals payable under operating leases are charged to the Statement of Financial Activities evenly over the period of the lease.

Grants payable

Grants payable are charged in the year when the offer is conveyed to the recipient except in cases where the offer is conditional, such grants being recognised as expenditure when the conditions are fulfilled.

Allocation and apportionment of costs

Costs have either been directly allocated or have been allocated on the basis of an estimate of time spent.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Equipment	– 25% on cost
Furniture	– 20% on cost

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Board of Trustees for particular purposes.

Restricted funds are subject to restrictions on their expenditure imposed by the donor or through the terms of appeal.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Notes to financial statements

Year ended 31 December 2022

2. Donations and legacies

	31.12.22 £	31.12.21 £
Donations	118,846	79,178
Grants	212,521	199,590
Fundraising activities	82,422	64,845
Income tax refund	11,622	23,439
Other income	–	35
	425,411	367,087

Grants received, included in the above, are as follows:

	31.12.22 £	31.12.21 £
Grants from NCG	56,886	55,310
Grants from European Commission	(4,551)	43,256
Grant from Medical Research Council	72,686	60,107
Grants from Trusts	87,500	40,917
	212,521	199,590

3. Other trading activities

	31.12.22 £	31.12.21 £
Sale of merchandise	1,592	1,190

4. Investment income

	31.12.22 £	31.12.21 £
Deposit account interest	2,142	63

5. Raising funds

	31.12.22 £	31.12.21 £
Staff costs	71,113	46,562
Information, literature, publicity etc.	3,521	6,106
Merchandise	949	330
Other direct costs	16,456	20,941
Support costs allocated to activities	25,400	18,872
	117,439	92,811

6. Charitable activities costs

	Research £	Clinic £	Welfare £	Information £	Education £	Governance £	2022 Total £	2021 Total £
Costs directly allocated to activities								
Staff costs	13,687	48,371	55,845	22,593	15,919	18,018	174,433	154,558
Support events	–	–	636	–	–	–	636	2,706
Newsletter	–	–	906	906	–	–	1,812	1,442
Welfare, equipment, respite etc.	–	–	23,597	–	–	–	23,597	3,200
Research costs and conference	14,777	–	–	–	–	–	14,777	19,469
Clinic costs	–	30,193	–	–	–	–	30,193	18,850
Information, literature, publicity	250	–	1,321	7,715	–	–	9,286	–
Other direct costs	–	–	–	–	–	10,172	10,172	10,074
Grant funding of activities	25,713	–	21,377	–	–	–	47,090	139,904
Support costs allocated to activities	3,930	12,934	16,967	7,598	5,636	4,906	51,971	57,620
	58,357	91,498	120,649	38,812	21,555	33,096	363,967	407,823

7. Analysis of grants

	31.12.22 £	31.12.21 £
Grants to institutions	25,713	121,673
Grants to individuals	21,377	18,231
	47,090	139,904

Grants to individuals are made to provide financial support grants to any individual affected by AT, to assist with the cost of items they need as a result of the condition. Grants to institutions are made to fund research.

The following grants to institutions have been made in the year:

	£
Natural History of Ataxia-Telangiectasia	(7,787)
Royal Papworth Hospital – the use of ultrasound (USS) in the assessment of people with Ataxia-Telangiectasia's ability to swallow versus use of videofluoroscopic swallow studies (VFSS)	3,500
Joint funding of 5 research projects*	30,000
	25,713

* research projects funded: 1) Brain-penetrating ATM gene therapy, 2) Study of natural killer cells in AT pathogenesis and their therapeutic implications, 3) Digital drug prediction informed by genetic analysis of stem cell-derived mini brains from AT patients, 4) Understanding and treating AT 5) Trial REadiness in AT

9. Operating lease commitments

The charity's total future minimum lease payments under non cancellable operating leases are as follows for each of the periods:

	Land & buildings		Equipment	
	2022	2021	2022	2021
Less than one year	–	15,819	5,866	5,866
Two to five years	–	–	16,038	20,143
More than five years	–	–	–	1,761
	–	15,819	21,904	27,770

10. Trustees' remuneration and benefits

No member of the Board of Trustees received any remuneration during the year (2021: £Nil).

Trustees' expenses

Travel expenses of £Nil were reimbursed during the year (2021: £Nil).

8. Net expenditure

Net expenditure is stated after charging:

	31.12.22 £	31.12.21 £
Auditors' remuneration	5,040	4,560
Depreciation – owned assets	964	794
Operating lease rentals – land and buildings	27,288	22,894
Operating lease rentals – equipment	5,845	5,885

11. Staff costs

	31.12.22 £	31.12.21 £
Salaries	217,424	178,504
Social security costs	16,089	12,007
Pension provision	12,033	10,609
	245,546	201,120

No employees had emoluments in excess of £60,000 (2021: none).

During the year the Society paid £54,010 in employee benefits to key management personnel for their services to the charity (2021: £52,022).

Notes to financial statements

Year ended 31 December 2022

11. Staff costs (continued)

During the year, the Society employed the equivalent of 6.5 full-time staff (2021: 5.5 FTE).

The company operates a defined contribution pension scheme in respect of the employees. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to £10,286 (2021: £8,786).

12. Comparatives for the statement of financial activities

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Income and endowments from:			
Donations and legacies	150,906	216,181	367,087
Charitable activities:			
Other trading activities	1,190	–	1,190
Investment income	63	–	63
	152,159	216,181	368,340
Expenditure on:			
Raising funds	92,811	–	92,811
Charitable activities:			
Research	137,291	42,648	179,939
Clinic	9,717	55,493	65,210
Welfare	8,037	73,719	81,756
Information	30,132	–	30,132
Education	17,987	–	17,987
Governance	32,799	–	32,799
	328,774	171,860	500,634
Net movement in funds	(176,615)	44,321	(132,294)
Reconciliation of funds			
Total funds brought forward	441,869	326,675	768,544
Gross transfers between funds	59,278	(59,278)	
Total funds carried forward	324,532	311,718	636,250

13. Tangible fixed assets

	Equipment £	Furniture £	Total £
Cost			
At 1 January 2022	16,798	4,472	21,270
Additions	1,284	–	1,284
At 31 December 2022	18,082	4,472	22,554
Depreciation			
At 1 January 2022	16,420	2,919	19,339
Charge for the year	447	517	964
At 31 December 2022	16,867	3,436	20,303
Net book value			
At 31 December 2022	1,215	1,036	2,251
At 31 December 2021	378	1,553	1,931

14. Debtors: amounts falling due within one year

	31.12.22 £	31.12.21 £
Trade debtors	4,784	–
Prepayments and accrued income	86,461	154,365
Other debtors	2,893	2,893
	94,138	157,258

Other debtors include a franking machine deposit of £200 which falls due in more than one year. Accrued income relates primarily to a grant of £72,686 from the Medical Research Council.

15. Creditors: amounts falling due within one year

	31.12.22 £	31.12.21 £
Support grants payable	2,270	4,791
Institutional grants payable	50,031	119,305
Trade creditors	1,099	956
Accruals and deferred income	12,260	7,849
Taxation and social security	5,299	3,901
	70,959	136,802

Grant funding commitments	Support grants £	Institutional grants £	Total £
Grant liability at 1 January 2022	4,791	119,305	124,096
Grants awarded in the year	21,377	25,713	47,090
Grants paid in the year	(23,898)	(94,987)	(118,885)

Grant liability at 31 December 2022	2,270	50,031	52,301
--	--------------	---------------	---------------

16. Contingent liabilities

Research grant funding	31.12.22 £	31.12.21 £
Natural History of Ataxia-Telangiectasia – Statistics Consultancy	3,500	3,500
Functional and metabolomic analysis of iPSC-derived Purkinje neurons from AT patients	30,000	30,000
Modulation of RELB/p52 – dependent NF-κB activities to improve neurodegenerative symptoms of AT	80,160	80,160
Joint funding of 5 research projects (see note 7)	30,000	–
	143,660	113,660

The above contingent liabilities relate to research grant funding where payment of the remaining funding is contingent on receipt of a satisfactory progress report from the institution in receipt of the award. It is anticipated that these contingent liabilities will be funded from designated research funds (see note 17) during 2023 and 2024.

17. Movement in funds

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	143,572	12,516	156,088
Designated research fund	180,960	27,795	208,755
	324,532	40,311	364,843

Restricted funds			
Research	7,014	11,185	18,199
Welfare, support, equipment	294,704	(96,542)	198,162
Information	10,000	(7,215)	2,785
	311,718	(92,572)	219,146
Total funds	636,250	(52,261)	583,989

Notes to financial statements

Year ended 31 December 2022

17. Movement in funds (continued)

	Incoming resources £	Resources expended £	Transfers in/(out) £	Movement in funds £
Unrestricted funds				
General fund	210,061	(256,677)	59,132	12,516
Designated research fund	–	(38,982)	66,777	27,795
	210,061	(295,659)	125,909	40,311
Restricted funds				
Research	79,041	(1,079)	(66,777)	11,185
Clinic costs	56,906	(56,906)	–	–
Welfare, support, equipment	82,637	(120,047)	(59,132)	(96,542)
Information	500	(7,715)	–	(7,215)
	219,084	(185,747)	(125,909)	(92,572)
Total funds	429,145	(481,406)	–	(52,261)

Purpose of restricted funds

Research

Restricted research income relates primarily to a grant received from the Medical Research Council to fund research projects. A transfer back to unrestricted designated funds has been made as the cost of these research projects was originally funded from unrestricted designated funds.

Clinic costs

Represents amounts received from NHS England in relation to our work supporting the specialist AT clinics run at Nottingham University Hospital and the Royal Papworth Hospital.

Welfare, support and equipment

The balance remaining represents provisions to fund work to support adults with AT to live more independently, plus funds restricted to particular items of equipment and geographical areas and to our welfare and communications work more broadly. Amounts spent in the year include the funding of a young adult activity weekend, emergency support grants, grants towards equipment for adults and young people, grants towards counselling, grants towards housing modifications and the funding of family support staff.

A transfer of £59,132 has been made from the restricted welfare fund back to general funds in respect of core costs advance funded from general funds but subsequently offset against a restricted legacy fund, the terms of which permit the funds to be used towards the core costs of the charity.

Information

The balance carried forward at the year end relates to funds to be used for the production of information materials in respect of AT.

Designated research fund

During 2019, the Board of Trustees designated £350,000 for research. During 2022, £38,982 (2021: £88,803) has been spent from this fund on research. A transfer of £66,777 has been made back to unrestricted designated reserves from restricted funds in respect of research expenditure initially made from unrestricted designated funds which was subsequently funded by restricted income received in the year. It is anticipated that the remaining designated funds will be spent during 2023 and 2024.

18. Related party disclosures

No trustee or any other person related to the charity had any personal interest in any contract or transaction entered into by the charity during the year or the previous year save as a potential beneficiary of the charity in the normal course of its activities.

19. Ultimate controlling party

In the opinion of the trustees, there was no controlling party during the year.

20. Statutory information

The Ataxia Telangiectasia Society is a private company, limited by guarantee, registered in England and Wales. The company's registered number and registered office address can be found on the facing page.

Trustees, patrons and advisors

Directors/Trustees



Michael Detsiny
Chair of Trustees



Andrew Mills
Treasurer
(resigned
October 2022)



David
MacDonald
Treasurer
(appointed
October 2022)



Dr Jayesh
Bhatt



Nicholas Gull



Professor
Penny Jeggo



Joe
Pemberton-
Powell



Rachel
Poupard



Jhilna Shah



Lian Yarlett

Patrons

Mrs Joan Bartholomew

The Lord Bilimoria of Chelsea CBE DL

Mr Brian Conley

The Lady Parkinson DL

The Revd Canon Paul Thomas OBE

Senior Management

Susie Norbury

Director of Fundraising & Operations

Kay Atkins

Head of Services

Professor Penny Jeggo

Head of Research

Scientific Advisory Board

Professor Rob Dineen

Chair

Dr Anke Hensiek

Professor Penny Jeggo

Professor Rick Livesey

Dr Cynthia Oviatt-Rothblum

Professor Laurence Pearl

Natasha Schneider

Professor Malcolm Taylor

Erik Thomassen

Dr William Whitehouse

Our Scientific Advisory Board expertly provide independent scientific advice on our research priorities, all in a voluntary capacity, to help shape AT research for the future.

Registered office and operational address

AT Society
Unit 54

Thrales End Business Centre

Thrales End Lane

Harpenden

Hertfordshire AL5 3NS

Telephone: 01582 760733

Email: info@atsociety.org.uk

Website: www.atsociety.org.uk

Company Registered in England
and Wales, Number: 5177145

Charity Commission Registered
in England, Number: 1105528

Auditors

Hicks & Company
Chartered Accountants
Statutory Auditors
Vaughan Chambers
Vaughan Road
Harpenden
Herts AL5 4EE

Bankers

The Co-operative Bank
PO Box 250
Skelmersdale WN8 6WT

HSBC Bank plc
1 High Street
Harpenden
Herts AL5 2RS

CAF Bank Ltd.
PO Box 289
West Malling
Kent ME19 4TA

**Our vision
is a world where
no one need suffer
from the devastating
effects of AT**

**Our mission is
to improve the quality
of life and quality of care
for people living with AT
while actively promoting
research to improve
treatments and ultimately
bring about a cure.**

To find out how you, or your organisation
can get involved in our work and help
change lives, please visit us:

AT^{*}SOCIETY.ORG.UK

*Ataxia Telangiectasia



Unit 54
Thrales End Business Centre
Thrales End Lane
Harpenden
Hertfordshire
AL5 3NS

01582 760733
info@atsociety.org.uk
www.atsociety.org.uk

Reg. Charity No. 1105528
Reg. Company No. 5177145



amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES